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ABSTRACT 
 
P-glycoprotein (Pgp), a protein codified by Multi Drug Resistance (MDR1) gene, has a detoxifying function 
and might influence the toxicity and pharmacokinetics and pharmacodynamics of drugs. Sampling strategies 
to improve Pgp studies could be useful to optimize the sensitivity and the reproducibility of efflux assays. 
This study aimed to compare Pgp expression and efflux activity by measuring Rhodamine123 (Rh123) 
retention in lymphocytes stored under different conditions, in order to evaluate the potential utility of any of 
the storing conditions in Pgp functionality. Our results show no change in protein expression of Pgp by 
confocal studies and Western blotting, nor changes at the mRNA level (qRT-PCR). No differences in Rh123 
efflux by Pgp activity assays were found between fresh and frozen lymphocytes after 24 hours of blood 
extraction, using either of the two Pgp specific inhibitors (VP and PSC833). Different working conditions in 
the 24 hours post blood extraction do not affect Rh123 efflux. These results allow standardization of Pgp 
activity measurement in different individuals with different timing of blood sampling and in different 
geographic areas.  
_______________________________________________________________________________________ 
 
INTRODUCTION 
 
P-glycoprotein (Pgp) is a multridug transporter 
that belongs to the ATP-Binding Cassette (ABC) 
family, and it is the product of the Multidrug 
Resistance-1 (MDR-1) gene. Pgp acts as a drug 
efflux pump extruding a range of different 
hydrophobic drugs from cells, contributing to 
drug disposition in humans and reducing the 
bioavailability of many orally administered 
medications. Pgp confers the multidrug resistant 
phenotype by maintaining reduced intracellular 
concentrations of anticancer drugs by virtue of its 
ability to act as a primary active transporter (1-3). 
As well, Pgp plays a role in the cells of the 
immune system, particularly in dendritic cell 
maturation and function (4,5). This multifaceted 
involvement in drug disposition, cancer drug 
resistance and regulation of the immune response 
makes Pgp an attractive target to deepen the 
optimization of different strategies and to foster a 
better understanding of its function in cells and 
tissues. 
Pgp works as a transporter molecule 
pumping a wide variety of endogenous substances  
 
 
and drugs from the cytoplasm to the exterior of 
the cell (6). Many widely used clinical agents are 
substrates, inhibitors or inducers of Pgp, including 
immunossupressive drugs (7). Therefore, Pgp 
plays a very important role in drug disposition 
(absorption, distribution, and excretion processes) 
(8,9). It is well known that Pgp is expressed 
constitutively at relatively high levels in many 
normal tissues such as intestinal epithelial cells, 
placenta, biliary canalicular cells, kidney, blood-
brain barrier and immune system cells such as 
lymphocytes (10-12). Regarding the wide tissue 
distribution and the effect on membrane transport 
of Pgp, the expression and activity of this protein 
could be essential in highlighting drug 
interactions. 
________________________________________ 
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ABBREVIATIONS  
 
Rhodamine123 (Rh123), P-glycoprotein (Pgp), 
ATP-Binding Cassette (ABC), Multidrug 
Resistance-1 (MDR-1), Annexin-V PE (AnnV),  
7-Aminoactinomycin D (7-AAD), Binding Buffer 
(BB), Phosphate Buffered Saline (PBS), Foetal 
bovine serum (FBS), fresh non-frozen 
lymphocytes (F/NFr), fresh frozen lymphocytes 
(F/Fr), non-fresh non-frozen lymphocytes 
(NF/NFr),  non-fresh frozen lymphocytes (NF/Fr), 
Mean fluorescence intensity (MFI), Verapamil 
(VP) and Flow analysis cell sorter (FACS).  
 
 
 
Measuring the protein level of Pgp is not 
always an indicator of the efflux activity of the 
protein. The MDR-1 activity controlling Pgp-
dependent drug transport depends on two factors: 
1) the level of expression of the MDR-1 gene that 
controls the amount of protein synthesized in the 
cells, where several single nucleotide 
polymorphisms in the MDR-1 gene have been 
identified, and 2) the functionality of the MDR-1-
encoded Pgp (13). 
Several methods have been developed to 
measure Pgp activity in blood samples (14-19). In 
all of them lymphocyte isolation and incubation 
with substrates (such as Rh123) in the presence or 
absence of specific Pgp inhibitors followed by 
FACS analysis are performed. Some authors carry 
out Pgp activity assays using lymphocytes 
isolated from fresh blood, which could be a 
limitation. Despite some uncontrolled factors such 
as co-medication (9,20), age (21,22) and inter-
individual differences in Pgp activity considered 
for result analysis (23), some methodological 
factors ought to be taken into account. There are 
no data comparing Pgp activity measured from 
fresh lymphocytes with cryo-preserved 
lymphocytes. Furthermore, most authors do not 
specify under which conditions cells are 
preserved and stored before measuring Pgp 
activity. The published studies do not specify 
whether they use lymphocytes isolated from fresh 
drawn blood, lymphocytes isolated within the 24 
hours after the drawing, frozen lymphocytes 
isolated from fresh drawn blood, or lymphocytes 
isolated from blood drawn and frozen within 24 
hours of the extraction and then thawed prior the 
assays. In view of the fact that Pgp is a labile 
protein and its activity could be lost depending on 
the temperature, these methodological factors 
should be considered because they determine the 
interval of time among blood collection, 
lymphocyte isolation and Pgp activity assays. 
Therefore, this present study aimed to 
compare Pgp expression and Rhodamine123 
(Rh123) retention in lymphocytes stored under 
different conditions to evaluate the potential 
influence of any of the storing conditions on Pgp 
expression and functionality.   
 
MATERIALS AND METHODS 
 
Drugs and Reagents 
 
The following drugs and reagents were used for 
the activity assays: Annexin-V PE (AnnV) (BD 
Pharmingen, CA, USA), 7-Aminoactinomycin D 
(7-AAD) (Sigma-Aldrich, Madrid, Spain), 
Binding Buffer (BB) (Medical and Biological 
Laboratories, Japan), Phosphate Buffered Saline 
(PBS) (PAA, Cambridge, UK), RPMI (Biological 
Industries, Israel), Rhodamine 123 (Molecular 
Probes Inc., USA), and PSC833 (kindly provided 
by Novartis, Basel, Switzerland). To select T 
lymphocytes from the whole lymphocyte 
population, CD3-APC conjugated Mouse anti-
Human monoclonal antibody (BD Pharmingen, 
CA, USA) was used. To detect P-glycoprotein in 
lymphocytes by Western blot, the antibody C-219 
was used (Calbiochem, Germany). 
 
Cell lines 
 
Two cell lines were used as a positive control for 
both the expression and the function of P-
glycoprotein. The cells lines used were 
SW1573/2R160, a Pgp-overexpressing cell line, 
and its counterpart SW1573 parental cell line. 
Both cell lines were cultured on DMEM 
supplemented with 10% FBS, 1% L-Glutamine, 
and 1% penicillin-streptomycin (Biological 
Industries, Israel), at 37ºC and 5% CO2 
atmosphere. The overexpression of Pgp in the 
SW1573/2R160 cell line was maintained by 
adding 160 nM of doxorubicin to the culture 
media every two to three passages. Both cell lines 
were a kind gift from Dr. G. Scheffer and Dr. R. 
Skepper of the Free University Medical Center, 
Amsterdam, The Netherlands. 
 
Human lymphocytes 
 
Informed consent was obtained from each healthy 
volunteer after the nature and possible 
consequences of the study were fully explained.  
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Written informed consent was obtained from all 
healthy volunteers in accordance with the 
Hospital Universitari de Bellvitge Ethic 
Committee. 
 
Lymphocyte isolation 
 
Lymphocytes were obtained from fresh venous 
blood from healthy volunteers, collected into 
EDTA tubes and kept at room temperature, and 
separated by standard Ficoll-Paque (Amersham 
Biosciences, UK) gradient centrifugation. After 
isolation, 25x106 lymphocytes were frozen in 
freezing media lymphocyte consisting of RPMI, 
20% DMSO and 20% FBS, 1:1, with FBS. Before 
activity assay, lymphocytes were rapidly thawed, 
washed twice with culture medium to free them of 
DMSO, and incubated for 2 hours at 37ºC and 5% 
CO2 in culture medium (RPMI supplemented with 
15% FBS and 1% L- Glutamine). In the non-
frozen group (F/NFr and NF/NFr), lymphocytes 
were incubated with culture medium for 2 hours 
before the assay. 
Blood sampling was performed in healthy 
volunteers (n=12, 6 men/ 6 women) ranging from 
23 to 53 years old. Four storage conditions of 
lymphocytes were used: fresh lymphocytes 
(F/NFr) (n=12), lymphocytes frozen immediately 
after the extraction (F/Fr) (n=12), lymphocytes 
isolated within 24 hours after the extraction 
(NF/NFr) (n=12) and lymphocytes isolated within 
24 hours after the extraction and immediately 
frozen (NF/Fr) (n=12).  
 
P-glycoprotein expression: Western Blot 
  
Membrane protein extracts were obtained by 
homogenizing lymphocytes in 100-300µl of lysis 
buffer (10mMTrisCl, 1.5mMMgCl2, 10mMKCl 
and 0.5% SDS) containing 4% protease inhibitor 
cocktail (Roche, Switzerland) and 2% PMSF. The 
extracts were stained on ice for 45 minutes and 
sonicated four times during that time. Then they 
were centrifuged for 10 minutes at 4ºC at 400 g, 
and the supernatant was recovered and ultra-
centrifuged for 1 hour at 4ºC at 18,000 g. The 
pellet was resuspended in 200µl of lysis buffer 
containing 4% protease inhibitor cocktail and 2% 
PMSF. Quantification of membrane proteins was 
done using the BCA Assay (Pierce, IL, USA), 
following the instructions of the manufacturer. 
80 µg of protein lysates were separated on to an 
8% SDS−polyacrylamide gel and transferred to 
PVDF membranes (BioRad, CA, USA). The 
membranes were blocked in 5% (w v-1) non-fat 
dry milk in Tris-buffered saline, pH 7.4, 
containing 0.1% Tween 20 (TBST) (50 mM Tris–
HCl, pH 7.5, 150 mM NaCl, 0.1% Tween-20)  at 
room temperature for 1 h. Blocked membranes 
were incubated with primary mouse antibodies 
specific to Pgp, C219 (1:100) (Calbiochem-
Novabiochem, San Diego, CA, U.S.A.) in TBST 
containing 5% BSA at 4°C overnight as described 
previously (24). After incubation, immunoblots 
were washed with TBST and incubated at room 
temperature for 1 h with the horseradish 
peroxidase conjugated antimouse secondary 
antibody (1:5000, Dako, Denmark) in TBST 
containing 5% milk. ECL detection kit (Pierce, 
IL, USA) was used to detect the protein bands. 
Pgp levels were expressed as a percentage of 
respective control groups. β-Actin (Cell Signaling 
Technology, Danvers, MA) was used as a 
comparator using antibody detection on stripped 
blots to confirm equal protein loading and 
blotting. 
 
P-glycoprotein mRNA level by quantitative 
real-time PCR (qRT-PCR) 
 
Total RNA was obtained following the Trizol 
manufacturer’s instructions (Invitrogen, 
Carlsbad). The RNA used for the study had a 
28s/18s ratio between 1.8 and 2.0. Total RNA was 
reverse-transcribed as follows: 2µg of RNA was 
incubated with 1µl of 50µM random hexamers 
followed by RNA denaturalization. Then, 5x 
reaction buffer was added, 0.4µl of 100mM dNTP 
mix, and MMLV retrotranscriptase 200u/µl 
(Ecogen, Langhorne, PA, USA) was added for a 
final volume of 20µl. The reaction was incubated 
for 5 min at 25ºC, followed by 30 min at 42ºC and 
85ºC for 5 min to stop the reaction. Real-time 
PCR was performed using 5µl of cDNA, primers 
and the TaqMan probe for MDR1 (Hs-
00184500_m1, Applied Biosystems, CA, USA), 
and the ABI Prism 7700 Sequence Detector. The 
level of target gene expression was determined 
using the Ct method as described previously 
(25), normalized to the GAPDH (Hs-
99999905_m1) control (Applied Biosystems, CA, 
USA). Results were expressed as many fold Pgp. 
Duplicates were carried out in each experiment. 
  
P-glycoprotein function in lymphocytes: Rh123 
retention assay 
 
500 l of the cell suspension (106 cells/ tube) in 
serum-free RPMI was added to 3 test tubes: 1 
tube, to evaluate cell auto-fluorescence: efflux 
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control (EC); 1 tube, to evaluate Rh123 efflux 
(E0), and the last tube, to evaluate the effect of 
PSC833 on Rh123 efflux (EV). 400 l of Binding 
Buffer (BB) was added to the EC tube. PSC833 
was added to the EV tube at a final concentration 
of 10µM. Then, 2.1 µl of Rh123 at 500 µM 
(0.525 µM final) dissolved in methanol was added 
to the E0 and EV tubes. All the tubes were 
incubated for 30 min at 37°C, avoiding light 
exposure. At the end of incubation, the tubes were 
kept on ice a few minutes to stop Pgp efflux 
activity. Cells were centrifuged for 10 min at 450 
g at 4°C and washed again with 2 ml of BB. After 
washing, the cells were diluted in 50 µl of BB 
containing 2 µl of CD3-APC, except for the EC 
tube, and incubated on ice for 30 min. 250 µl of 
BB containing 2µl AnnV (to detect apoptotic 
cells) and 2µl of 7-AAD (to detect cells with 
membrane damage) were added in all tubes 
except the EC and incubated for 15 min on ice 
avoiding light exposure, prior to flow cytometry 
analysis. The samples were acquired on a 
FACSCalibur flow cytometer (Becton and 
Dikinson, BD) with four-color analysis. 10,000 
CD3+ events were acquired and analyzed using 
CellProQuest software (BD). The instrument 
settings were established first and compensation 
was adjusted by acquiring cells stained with each 
fluorochrome. FSC and SSC were collected using 
linear scales and fluorescence signals were 
collected using logarithmic scales. All the data 
were collected in list mode. Results were 
expressed as the mean fluorescence intensity 
(MFI). Efflux activity was calculated as (MFI of 
Rh123 (FL1) (EV) - MFI of Rh123 (E0))/ (√sd2 
(EV)+ sd2 (EO)), while retention ratio was 
calculated as (MFI of Rh123 (EV)/ MFI of Rh123 
(EO)). Each experiment was performed three 
times. 
The same protocol was performed with 
the first generation Pgp inhibitor Verapamil, using 
a range of different concentrations (10 to 50µM) 
to establish the best functional and non-toxic 
concentration, at 20 µM for lymphocytes and 40 
M for the SW1573 cell lines.  
 
Statistical Analysis  
 
Rh123 retention of the four conditions of 
lymphocytes was measured in n=12 healthy 
volunteers. The activity was measured both in 
AnnV negative and 7-ADD negative population, 
and apoptotic (AnnV positive population) 
lymphocytes. Non-parametric statistical analysis 
was performed, using the non-parametric Mann-
Whitney test to compare the activity of F/Fr, 
NF/NFr and NF/Fr CD3+ cells to the activity of 
F/NFr CD3+ lymphocytes. The analysis was 
performed both within the viable and the 
apoptotic lymphocytes, and also between viable 
and apoptotic lymphocytes.  
 
RESULTS  
 
1. Pgp lymphocyte expression under four 
different storage conditions  
 
Western Blot. Pgp expression in lymphocytes was 
measured and compared in all storage conditions. 
The four conditions showed no differences in the 
protein levels (Fig 1). Pgp is a protein that is 
glycosylated in several positions, adopting 
different molecular weights, as can be seen in the 
overexpressing Pgp cell line SW1573/2R160 used 
as a positive control. 
 
 
 
 
 
 
 
 
 
 
Figure 1. Pgp expression in CD3+ lymphocytes by 
Western blot analysis. Membrane protein extracts 
(80g) from each of the lymphocyte conditions were 
separated in a SDS-polyacrylamide gel, and Pgp was 
detected with a specific antibody (C219). A positive 
cell line control that over-expresses Pgp was used 
(SW1573/2R160). All conditions showed a similar 
band in the170 KDa molecular weight. The different 
mobility observed in the positive control is due to 
different degrees of post-transductional modifications 
(glycosilation) of the protein. 
 
 
Quantitative Real Time PCR. The expression of 
Pgp mRNA was measured to look for evidence of 
differences among the four storage conditions 
with the healthy volunteers. No statistical 
differences were found at the expression level of 
the transporter in the four conditions (F/NFr = 
1.0±0, F/Fr = 0.9±0.33, NF/NFr= 0.74±0.12 and 
NF/Fr = 0.68±0.51), suggesting that freezing 
lymphocytes does not affect Pgp mRNA 
expression (p>0.05) (Fig. 2).  
 
 
 
F/NFr SW1573/2R160F/Fr NF/NFr NF/Fr
190 KDa
170 KDa
ß-actin
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Figure 2. Pgp expression in CD3+ lymphocytes at the mRNA level by qRT-PCR. The expression of Pgp was measured 
by quantitative real-time PCR in the four conditions established in 12 healthy human volunteers. No significant 
differences were found related to F/NFr control group. 
 
 
2. Flow cytometry analysis of Rh123 retention 
in lymphocytes 
 
To assess which CD3+ lymphocytes were the 
optimal for studying Pgp activity, retention 
experiments using Rh123 were performed using 
viable CD3+ T lymphocytes (AnnV- and 7ADD+), 
excluding the early apoptotic (AnnV+ and 7ADD-
), late apoptotic or necrotic (AnnV+ and 7ADD+) 
populations in different lymphocytes conditions. 
The four conditions of viable lymphocytes had a 
similar retention of Rh123 in the presence or 
absence of any of the inhibitors, showing a 
retention ratio of 2.05±0.10 for VP and 1.36±0.07 
for PSC833 (Table 1) as an average value of the 
four conditions. 
 To assess whether freezing lymphocytes 
could modify Pgp activity, retention experiments 
in healthy volunteer lymphocytes were done. 
Rh123 retention in the CD3+ T viable cells was 
analyzed by FACS in the presence or absence of 
the inhibitors. Results were expressed in the four 
conditions by subtracting the mean channel of 
Rh123 MFI from the mean channel number of 
Rh123 MFI in the presence of VP or PSC833. As 
Figure 3 shows, the four conditions of 
lymphocyte demonstrated similar patterns of 
retention of Rh123 both in the absence and 
presence of the inhibitor. Pgp activity in the 
presence of the inhibitors in the four conditions 
resulted in an increase of approximately one 
logarithm of MFI compared with Rh123 alone. 
Therefore, no significant differences in Pgp 
activity were found. Results showed no inter-
individual differences in F/NFr vs NF/NFr, F/Fr 
or NF/Fr in CD3+ viable cells (Table 2). 
Additionally, we analyzed the differences of Pgp 
activity within the same individual in the four 
conditions in viable cells; no significant 
differences were found (p=0.183) (data not 
shown).  
 
3. Rh123 retention assay in viable versus early 
apoptotic lymphocytes 
 
Pgp activity in the early apoptotic CD3+ cell 
population (AnnV+/7-ADD-) was not statistically 
different when comparing the four conditions 
(F/Fr (p=0.66), NF/NFr (p=0.71) and NF/Fr 
(p=0.87)), taking the F/NFr condition as a 
reference (Fig 4A). The Pgp activity observed in 
the apoptotic population was lower (p<0.05) than 
the activity in viable lymphocytes, probably due 
to the loss of functionality of the cell, and there 
was higher variability among different individuals 
compared to viable cells (Fig 4B). It should be 
mentioned that the apoptotic population 
represents a low percentage of the total CD3+ 
lymphocytes (4.5%). Therefore it was not 
considered in the Pgp activity analysis. 
When measuring cell viability in the four 
conditions, CD3+ population was viable between 
90% (F/NFr, NF/NFr) and 80% (F/Fr, NF/Fr). 
The early and late apoptotic and necrotic cells 
represented a minority of the lymphocyte 
population (Fig 5A). These results indicate that 
freezing lymphocytes partially modifies cell 
viability (Fig 5B).  
 
 
1.5 
1 
0.5 
0 
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Table 1. Rh123 retention in the four conditions of viable CD3+ using two Pgp inhibitors: VP and PSC833. 
 
 VP((MFI) Non VP(MFI) Retention 
ratio 
PSC833(MFI) Non PSC833 
(MFI) 
Retention 
ratio 
 
F/NFr 
 
1232.09±117.40 
 
609.87±150.02 
 
2.02±0.06 
 
1576.37±117.47 
 
1237.76±91.37 
 
1.27±0.05 
F/Fr 1629.97±164.18 744.07±113.23 2.19±0.11 2279.03±146.67 1657.29±118.6
4 
1.34±0.07 
NF/NFr 822.57±108.2 408.18±78.56 2.02±0.09 1598.53±120.20 1154.34±97.38 1.38±0.06 
NF/Fr 1520.5±149.12 777.19±95.48 1.96±0.12 2262.00±120.77 1574.07±98.65 1.43±0.09 
mean±sd   2.05±0.10   1.36±0.07 
 
MFI of Rh123 was measured after 30 min exposure in the presence and absence of the Pgp inhibitors VP and 
PSC833.  When Pgp was blocked by VP, the four conditions of lymphocytes retained double the amount of 
Rh123 MFI without inhibitor (2.05±0.10); when using PSC833, the retention ratio was 1.36±0.07. Results are 
expressed as the mean of MFI of Rh123 of 12 healthy volunteers. No significant differences in Rh123 retention 
were seen among the four conditions studied with the two inhibitors used (p=NS). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Pgp retention ratio of Rh123 in human lymphocytes measured by Flow cytometry analysis (FACs). 
Pgp retention ratio in the four conditions was measured in viable CD3+ lymphocytes (AnnexinV-/7ADD-) by Rh123 
retention measurements detected by FACS. Retention was measured as mean fluorescence intensity (MFI) of Rh123 in 
a logarithmic scale. Retention of Rh123 by Pgp was estimated as a logarithm increase of MFI of Rh123 when a Pgp 
inhibitor is added. A.1 The Pgp retention of the Rh123 plot of the four conditions overlapped, meaning that Pgp activity 
was not modified due to the storing and sample manipulation. A.2. When VP was used to block Pgp, an increase in one 
logarithm of MFI of Rh123 was observed in all four conditions where the plots also overlapped. B.1 and B.2. The same 
results were observed when PSC 833 was used to inhibit Pgp activity. 
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Figure 4. Pgp activity in apoptotic lymphocytes. Pgp activity was measured in the T cells’ early apoptotic population 
(CD3+/AnnV+/7-ADD-) by Rh123 retention assays. A. Mean (n=12) of the activity measured in the four conditions of 
apoptotic lymphocytes. B. High variability was found in the activity measured within intra-individuals comparing the 
four conditions. 
 
 
Table 2. Effect of storage conditions in the Pgp 
activity in CD3+ viable cells. 
 VP PSC833 
F/NFr 0.121± 0.061 0.247± 0.138 
F/Fr 0.184± 0.071 0.326± 0.136 
NF/NFr 0.134± 0.058 0.331± 0.097 
NF/Fr 0.215± 0.095 0.337± 0.202 
p NS NS 
 
Pgp activity, calculated as (MFI of Rh123 in the 
presence of inhibitor (EV) - MFI of Rh123 in the 
absence of inhibitor (E0))/(√sd2 (EV)+ sd2 (EO)), was 
expressed as mean  sd of 12 healthy volunteers (p= 
NS). 
 
 
 
DISCUSSION 
 
In this study, the expression of Pgp and Rh123 
retention in lymphocytes handled and stored 
under four different conditions was measured, and 
our results showed no significant differences 
among the storage conditions. To date, studies by 
other groups have not specified the processing 
and storing conditions of the cells before analysis. 
Some groups performed Rh123 retention assays 
directly from fresh whole blood (26), and others 
from fresh isolated lymphocytes (27), but the 
majority of the studies have not indicated whether 
the lymphocytes were isolated from freshly drawn 
blood or blood stored at room temperature for a 
short period of time (28). The main interest of the 
present study is to show that Pgp expression and 
activity measured through Rh123 retention are not 
modified when blood is kept at room temperature 
for 24 hours nor when the lymphocyte isolation is 
carried out immediately after the blood is drawn. 
Peripheral mononuclear cells are known 
to express ABC efflux transporters. Hence, 
isolated cells could be useful to study drug-
transporters in the in vivo/ex vivo monitoring of 
the potential effects of drugs on the expression 
and activity of these transporters. There is clear 
evidence that normal blood cells, particularly 
natural killer (NK) cells and T lymphocytes, 
express Pgp (29), although the level of Pgp 
expression on lymphocytes does not imply a 
direct correlation with Pgp activity (30). This lack 
of correlation between Pgp expression and 
activity may be explained, in part, by the fact that 
functional analysis based on Pgp substrate dyes 
such as Rh123 is much more sensitive in the 
detection of low-level multidrug resistance than 
Pgp expression analysis (31,32). Although NK 
cells play an important role in Pgp expression and 
function, this subpopulation represents a low 
percentage of the PBMC population. Therefore, 
considering that the CD3+ cells represent a high 
percentage of the PBMC, as they show functional 
Pgp expression and play a predominant role in 
immune response, this population was the most 
suitable for the purpose of the present study. 
It has to be considered that Pgp is a 
fragile protein and could be inactivated by 
freeze/thawing cycles (33). Therefore 
manipulation of lymphocytes could be extremely 
critical in this regard.  
Figure 4A Figure 4B 
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Figure 5. Cell viability in the four conditions of lymphocytes. A. In each lymphocyte condition cell viability was 
measured, distinguishing among viable (CD3+/AnnV-/7-ADD-), early apoptotic (CD3+/AnnV+/7-ADD-), late apoptotic 
and necrotic (CD3+/AnnV+/7-ADD+) cells. In all four conditions viable cells were the vast majority. B. Pgp activity in 
viable and apoptotic CD3+ lymphocytes.  
 
 
The manner of drawing, isolating and 
storing lymphocytes is a relevant key toward 
obtaining good reproducibility for the Pgp activity 
studies. For multicentre studies, where blood is 
collected from different centers and Pgp substrate 
retention assays have to be performed from 
lymphocytes isolated and/or stored under different 
conditions, it is critical to guarantee uniformity of 
the procedure conditions for all the samples.  In 
the present study, lymphocytes were frozen and 
no significant changes in the expression or the 
activity of the Pgp protein were found. 
One approach to measuring Pgp activity 
was the retention of Rh123 within the cells, in the 
presence and absence of Pgp inhibitors. The two 
efflux pump inhibitors used were the Ca+2 channel 
blocker VP and PSC833, a Pgp selective inhibitor, 
also known as Valspodar. The two inhibitors 
showed no differences in the Rh123 retention 
among the four conditions of the lymphocytes 
studied.  Nevertheless, PSC833 is a more specific 
and potent inhibitor of Pgp than VP, as the 
concentration used to inhibit Ppg efflux was half 
the concentration of VP. 
Within the CD3+ population, three cell 
subsets were compared in terms of Pgp efflux 
activity calculated by Rh123 retention 
measurements: viable, early apoptotic and late 
apoptotic lymphocytes. Although early apoptotic 
lymphocytes prove Pgp efflux activity, this 
population represents only 4.5% of the total 
lymphocytes purified from the blood samples. 
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Therefore, not measuring the activity of the early 
apoptotic lymphocytes does not alter the results of 
activity obtained from viable population. In 
contrast, late apoptotic and necrotic cells should 
be considered separately or excluded because they 
always show background activity that interferes in 
the analysis of the viable lymphocyte Rh123 
retention measurements. We established that in 
order to obtain the most accurate results, the 
apoptotic population should be considered 
separately and necrotic cells should be excluded. 
 
CONCLUSIONS 
 
Our results show that for the 24 hours post blood 
extraction, Pgp activity measured by Rh123 
retention was not affected by the 4 different 
handling processes. They also confirm that in 
order to assess global Pgp activity, Pgp should be 
analyzed in viable cells, removing the necrotic 
population. These parameters could contribute to 
improve Pgp activity studies in individuals with 
different blood sampling timing and/or different 
geographic areas. 
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